Redeye has a positive take on Nanexa's intention to develop a long-acting formulation of lenalidomide (Brand name Revlimid) for the treatment of multiple myeloma, a form of blood cancer. We think that the start of NEX 20 in combination with the earlier announced collaboration with Applied Materials together demonstrates Nanexa's long term potential and vision. While we do not change our valuation overnight, we now see good reason to review our fair value range of Nanexa.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se